How to Use an LAI Before Confirming Treatment-Resistant Psychosis
How should clinicians use a long-acting injectable antipsychotic before concluding that persistent psychosis is treatment resistant?
In early phase schizophrenia and related disorders, persistent positive symptoms may reflect either true inadequate response or covert, partial, or complete nonadherence to oral antipsychotics. This matters because clozapine decisions depend on distinguishing breakthrough symptoms despite confirmed treatment from relapse caused by medication discontinuation or inconsistent use.
-
Identify persistent symptoms or relapse despite antipsychotic treatment
Use this workflow when a patient in coordinated specialty care continues to have positive symptoms or relapses while prescribed antipsychotic medication. The article highlights residual positive symptoms and poor attitudes toward medication taking as major risk factors for hospitalization in this population.
-
Consider adherence uncertainty before labeling treatment resistance
Pause before assuming the patient has treatment-resistant schizophrenia if treatment exposure has depended on oral medication adherence alone. The article notes that adherence early in illness is often poor and cites evidence that one-third of patients referred to a treatment-resistant schizophrenia program had subtherapeutic or nondetectable antipsychotic blood levels.
-
Trial a long-acting injectable antipsychotic
Use an LAI when adherence is in doubt because it gives the clinical team a conclusive assessment of whether medication is being taken as prescribed. The article states that TRIPP Working Group guidelines recommend a trial of an LAI antipsychotic before confirming treatment resistance.
-
Observe whether relapse represents nonadherence or breakthrough on medication
During LAI treatment, determine whether ongoing psychosis or relapse still occurs when medication delivery is assured. The article describes this as distinguishing nonadherence-related relapse from breakthrough on antipsychotic medication, a distinction clinicians often judge inaccurately without the adherence confirmation an LAI provides.
-
Apply treatment-resistance criteria only after adequate confirmed treatment
Traditional treatment resistance is described in the article as failure to respond to 2 or more prior treatments with different antipsychotics, each for 6 weeks or longer at a therapeutic dosage equivalent to 600 mg or more of chlorpromazine per day, with at least 1 prior treatment using an LAI for 4 months or longer. If these conditions are met and positive symptoms persist, the patient more clearly fits a putative treatment-resistant pathway relevant to clozapine consideration.
Clinical Considerations
- The article emphasizes uncertainty among clinicians about whether relapse despite taking antipsychotic medication should automatically qualify as treatment resistance.
- Breakthrough on antipsychotic medication can occur even with LAIs, so persistence of symptoms during LAI treatment does not by itself resolve all treatment-resistance questions.
- This article discusses the rationale for an LAI trial before confirming treatment resistance but does not provide a drug-specific LAI selection protocol.
Bottom Line
Before labeling early psychosis as treatment resistant, use an LAI to confirm actual antipsychotic exposure and separate nonadherence from true inadequate response.
